Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation

Promyelocytic leukemia (PML) is the organizer of nuclear matrix domains, PML nuclear bodies (NBs), with a proposed role in apoptosis control. In acute promyelocytic leukemia, PML/retinoic acid receptor (RAR) α expression disrupts NBs, but therapies such as retinoic acid or arsenic trioxide (As2O3) restore them. PML is conjugated by the ubiquitin-related peptide SUMO-1, a process enhanced by As2O3 and proposed to target PML to the nuclear matrix. We demonstrate that As2O3 triggers the proteasome-dependent degradation of PML and PML/RARα and that this process requires a specific sumolation site in PML, K160. PML sumolation is dispensable for its As2O3-induced matrix targeting and formation of primary nuclear aggregates, but is required for the formation of secondary shell-like NBs. Interestingly, only these mature NBs harbor 11S proteasome components, which are further recruited upon As2O3 exposure. Proteasome recruitment by sumolated PML only likely accounts for the failure of PML-K160R to be degraded. Therefore, studying the basis of As2O3-induced PML/RARα degradation we show that PML sumolation directly or indirectly promotes its catabolism, suggesting that mature NBs could be sites of intranuclear proteolysis and opening new insights into NB alterations found in viral infections or transformation.

[1]  Mounira K Chelbi-Alix,et al.  Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins , 1999, Oncogene.

[2]  R. Evans,et al.  Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Pandolfi,et al.  A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins , 1999, Nature Genetics.

[4]  P. Pelicci,et al.  Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. , 1998, Blood.

[5]  E. Milgrom,et al.  Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. , 1995, Molecular endocrinology.

[6]  R. Hay,et al.  SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. , 1998, Molecular cell.

[7]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[8]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[9]  P. Freemont.  Ubiquitination: RING for destruction? , 2000, Current Biology.

[10]  P. Freemont,et al.  The Disruption of ND10 during Herpes Simplex Virus Infection Correlates with the Vmw110- and Proteasome-Dependent Loss of Several PML Isoforms , 1998, Journal of Virology.

[11]  E. Ward,et al.  Negative Selection during the Peripheral Immune Response to Antigen , 2001, The Journal of experimental medicine.

[12]  J. Yewdell,et al.  Intracellular Localization of Proteasomal Degradation of a Viral Antigen , 1999, The Journal of cell biology.

[13]  P. Chambon,et al.  Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.

[14]  B. Humbel,et al.  A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. , 1992, Journal of cell science.

[15]  R. van Driel,et al.  Cell cycle regulation of PML modification and ND10 composition. , 1999, Journal of cell science.

[16]  P. Freemont,et al.  SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. , 1999, Journal of cell science.

[17]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[18]  C. Peschle,et al.  Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. , 1998, Journal of the National Cancer Institute.

[19]  R. Evans,et al.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.

[20]  A. Dejean,et al.  Conjugation with the ubiquitin‐related modifier SUMO‐1 regulates the partitioning of PML within the nucleus , 1998, The EMBO journal.

[21]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[22]  Jennifer O'Neil,et al.  Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML , 2000, Molecular and Cellular Biology.

[23]  P. Pandolfi,et al.  Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression , 2001, The Journal of experimental medicine.

[24]  F. Lo Coco,et al.  Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. , 1992, The EMBO journal.

[25]  A. Weissman,et al.  RING Finger Proteins Mediators of Ubiquitin Ligase Activity , 2000, Cell.

[26]  R. Evans,et al.  Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Lowe,et al.  PML is induced by oncogenic ras and promotes premature senescence. , 2000, Genes & development.

[28]  D. Levy,et al.  Proto-oncogene PML controls genes devoted to MHC class I antigen presentation , 1998, Nature.

[29]  S. Pileri,et al.  Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. , 1995, Blood.

[30]  H. de Thé,et al.  PML protein expression in hematopoietic and acute promyelocytic leukemia cells. , 1993, Blood.

[31]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[32]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[33]  M. Koken,et al.  PML induces a novel caspase-independent death process , 1998, Nature Genetics.

[34]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[35]  P. Pandolfi,et al.  Promyelocytic Leukemia Protein (Pml) and Daxx Participate in a Novel Nuclear Pathway for Apoptosis , 2000, The Journal of experimental medicine.

[36]  A. Dejean,et al.  Viral Immediate-Early Proteins Abrogate the Modification by SUMO-1 of PML and Sp100 Proteins, Correlating with Nuclear Body Disruption , 1999, Journal of Virology.

[37]  P. Thomas,et al.  Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. , 2001, Journal of cell science.

[38]  A. Saïb,et al.  Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. , 1995, Oncogene.

[39]  B. Henderson,et al.  A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. , 2000, Experimental cell research.

[40]  John Calvin Reed,et al.  Human Daxx regulates Fas‐induced apoptosis from nuclear PML oncogenic domains (PODs) , 1999, The EMBO journal.

[41]  E. Yeh,et al.  Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins* , 1998, The Journal of Biological Chemistry.

[42]  P. Pandolfi,et al.  Regulation of Pax3 transcriptional activity by SUMO-1-modified PML , 2001, Oncogene.

[43]  E. Yeh,et al.  Identification of Three Major Sentrinization Sites in PML* , 1998, The Journal of Biological Chemistry.

[44]  E. Yeh,et al.  Pml Is Critical for Nd10 Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure When Modified by Sumo-1 , 1999, The Journal of cell biology.

[45]  P. Pandolfi,et al.  Role of SUMO-1-modified PML in nuclear body formation. , 2000, Blood.

[46]  H. de Thé,et al.  Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Kawasaki,et al.  A Critical Role for the Proteasome Activator PA28 in the Hsp90-dependent Protein Refolding* , 2000, The Journal of Biological Chemistry.

[48]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[49]  F. Melchior,et al.  A Small Ubiquitin-Related Polypeptide Involved in Targeting RanGAP1 to Nuclear Pore Complex Protein RanBP2 , 1997, Cell.

[50]  A. Matera,et al.  Nuclear bodies: multifaceted subdomains of the interchromatin space. , 1999, Trends in cell biology.